Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Author:
Affiliation:
1. Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA;
2. H. Lundbeck A/S, Valby, Copenhagen, Denmark
Funder
Otsuka Pharmaceutical Development & Commercialization Inc.
Publisher
Informa UK Limited
Subject
General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1430220
Reference29 articles.
1. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder
3. The Cost Consequences of Treatment-Resistant Depression
4. If at First You Donʼt Succeed
5. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics;Molecular Biology Reports;2024-01-28
2. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double‐blind (BLESS) study;Psychiatry and Clinical Neurosciences;2023-12
3. A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics;Neuropsychiatric Disease and Treatment;2023-12
4. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis;Medicine;2023-09-22
5. Brexpiprazole versus placebo or other antidepressive agents for treating depression;Cochrane Database of Systematic Reviews;2023-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3